Dr. Samuel Benjamin Brusca, MD

Dr. Brusca practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Brusca's NPI, 1174942148, was assigned on April 7, 2014. Dr. Brusca graduated from New York University School of Medicine in 2014. Dr. Brusca holds California license A168461.

Dr. Brusca's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Brusca's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Brusca is also affiliated with UCSF Health Stanyan Hospital. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Brusca to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brusca practices, 2 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Brusca's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Brusca is licensed in California.

CMS data shows 739 Medicare services from Dr. Brusca across 10 procedure codes in 2024, for 220 Medicare patients. Medicare paid $97,268 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 220 Medicare patients who saw Dr. Brusca in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have heart failure, and 75% have high blood pressure. 51% are also on Medicaid. Their average risk score is 3.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brusca's median patient age at 62, with 42% women.

In 2024, Dr. Brusca wrote 134 Medicare Part D claims for 23 patients. 68% of them were for generic drugs. CMS names the drug for 105 of them, across 6 drugs with 11 or more claims each, at $343,738 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Brusca for performance year 2024, reported as part of a group. Dr. Brusca accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brusca as offering telehealth.

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 14 papers to Dr. Brusca, published from 2020 to 2024. 2022 was the busiest year, with 3. The most frequent topics are COVID-19, SARS-CoV-2 and Shock, Cardiogenic. Dr. Brusca has published most often in JACC Adv. Dr. Brusca's most frequent co-authors are Christopher F. Barnett, MD, MPH, Michael A. Solomon, MD and Erin Ann Bohula, MD.

CMS Open Payments shows 12 general payments to Dr. Brusca from 4 drug and device companies from 2023 to 2025. Consulting fees make up the largest share, 83% of the total. Actelion Pharmaceuticals US, Inc. paid the most, $2,942.

Dr. Brusca graduated from New York University School of Medicine in 2014.